These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3285 related items for PubMed ID: 3800331

  • 1. In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin.
    Zupi G, Greco C, Laudonio N, Benassi M, Silvestrini B, Caputo A.
    Anticancer Res; 1986; 6(5):1245-9. PubMed ID: 3800331
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In vitro potentiation by lonidamine of the sc-RIP saporin 6 effect in a human metastatic breast cancer cell line.
    Roncuzzi L, Zoli W, Bajorko P, Gasperi-Campani A.
    Anticancer Res; 1995; 15(3):773-6. PubMed ID: 7645957
    [Abstract] [Full Text] [Related]

  • 4. Doxorubicin plus lonidamine: in vivo metabolic effects on the rat heart.
    Neri B, Lottini G, Bandinelli E, Cini-Neri G.
    Anticancer Drugs; 1991 Aug; 2(4):401-4. PubMed ID: 1797197
    [Abstract] [Full Text] [Related]

  • 5. Modification of tumor cell sensitivity to antineoplastic agents lonidamine and bouvardin (NSC 259968) at elevated temperatures.
    Adwankar MK, Chitnis MP.
    Neoplasma; 1986 Aug; 33(2):217-23. PubMed ID: 3713924
    [Abstract] [Full Text] [Related]

  • 6. [Synergistic role between rhIL-2 and adriamycin long circulating temperature-sensitive liposome in targeting therapy on tumor].
    Dong LF, Mei HS, Song SX, Lu ZJ.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 May; 21(3):296-300. PubMed ID: 15862144
    [Abstract] [Full Text] [Related]

  • 7. Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro.
    Ning SC, Hahn GM.
    Cancer Res; 1990 Dec 15; 50(24):7867-70. PubMed ID: 2253227
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
    Quintieri L, Rosato A, Napoli E, Sola F, Geroni C, Floreani M, Zanovello P.
    Cancer Res; 2000 Jun 15; 60(12):3232-8. PubMed ID: 10866316
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Anti-tumor effect of monkshood polysaccharide with adriamycin long circulating temperature-sensitive liposome and its mechanism].
    Dong LF, Zhang YJ, Liu JS, Song SX, Hou J, Lu ZJ.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Jul 15; 22(4):458-62. PubMed ID: 16806008
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of lonidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumor xenograft.
    Pratesi G, De Cesare M, Zunino F.
    Cancer Chemother Pharmacol; 1996 Jul 15; 38(2):123-8. PubMed ID: 8616901
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.
    Ponthan F, Wickström M, Gleissman H, Fuskevåg OM, Segerström L, Sveinbjörnsson B, Redfern CP, Eksborg S, Kogner P, Johnsen JI.
    Clin Cancer Res; 2007 Feb 01; 13(3):1036-44. PubMed ID: 17289900
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
    Ianniello GP, De Cataldis G, Comella P, Scarpati MD, Maiorino A, Brancaccio L, Cioffi R, Lombardi A, Carnicelli P, Tinessa V.
    Cancer; 1996 Jul 01; 78(1):63-9. PubMed ID: 8646728
    [Abstract] [Full Text] [Related]

  • 20. 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent.
    Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y.
    Cancer Res; 1982 Apr 01; 42(4):1462-7. PubMed ID: 7060020
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 165.